PCI Biotech Holding ASA (LON:0JGL)
0.2470
+0.0090 (3.78%)
Feb 11, 2026, 11:06 AM GMT
PCI Biotech Holding ASA Revenue
PCI Biotech Holding ASA had revenue of 1.38M NOK in the half year ending June 30, 2025, with 230.70% growth. This brings the company's revenue in the last twelve months to 4.69M, down -21.85% year-over-year. In the year 2024, PCI Biotech Holding ASA had annual revenue of 6.74M with 125.25% growth.
Revenue (ttm)
4.69M NOK
Revenue Growth
-21.85%
P/S Ratio
1.95
Revenue / Employee
901.54K NOK
Employees
5
Market Cap
658.16K GBP
Revenue Chart
* This company reports financials in NOK.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 6.74M | 3.75M | 125.25% |
| Dec 31, 2023 | 2.99M | -1.76M | -37.05% |
| Dec 31, 2022 | 4.75M | -1.52M | -24.28% |
| Dec 31, 2021 | 6.27M | -1.10M | -14.86% |
| Dec 31, 2020 | 7.37M | -2.02M | -21.55% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.64B |
| GSK plc | 32.67B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Kanabo Group | 1.14M |
| Physiomics | 834.16K |
| Imaging Biometrics | 699.86K |
| Chill Brands Group | 305.70K |